DELRAY BEACH, Fla., Jan. 02, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (the “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that its Chairman and CEO, William J. Caragol, discussed the Company’s 2017 accomplishments in a new interview with CEOLIVE.TV. The interview can be heard at http://ceolive.tv/positiveid-corp-psid-ceo-discusses-2017-highlights-for-its-molecular-diagnostics-business/.
In the interview, Caragol reaffirmed that he projects consolidated year-over-year revenue growth of more than 30% for the 2017 fourth quarter and 2018 first quarter due to a strong backlog of business and pipeline opportunities for its mobile labs and medical device businesses.
PositiveID operates in three segments: Mobile Labs, comprised of its E-N-G Mobile Systems, Inc. subsidiary, a specialty vehicle manufacturer; Medical Devices, comprised of its Thermomedics subsidiary, which markets the Caregiver® non-contact thermometer; and Molecular Diagnostics, comprised of its ExcitePCR Corporation subsidiary, consisting of its FireflyDX family of products for real-time pathogen detection at the point-of-need/point-of-care.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
On August 24, 2017, PositiveID Corporation and its wholly-owned subsidiary PositiveID Diagnostics, Inc. (collectively, the “Seller”), entered into an Asset Purchase Agreement (“APA”) with ExcitePCR Corporation. Pursuant to the APA, at closing, the Seller will sell and deliver to ExcitePCR all assets used in connection with the operation of the FireflyDX technology. For more information on the APA, please read PositiveID’s Form 8-K filed on August 28, 2017, which can be found here.
Statements about PositiveID's future expectations, including the likelihood that the Company will deliver consolidated year-over-year revenue growth of more than 30% for the 2017 fourth quarter and 2018 first quarter; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to complete the development, testing and commercialization of the FireflyDX-Portable and FireflyDX-Handheld; the Company’s ability to target the professional healthcare market; the Company’s ability to raise capital; the Company’s and ExcitePCR’s ability to close the APA; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on November 13, 2017, August 14, 2017, and May 15, 2017, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.